



3. RESIDUAL ASCVD RISK & OTHER PLAYERS IN DYSLIPIDEMIA

Important Guidelines, Statements, and Reports

- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis (+)
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee (+)
- Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline (+)
- Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factors for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association (+)

Important Suggested Readings and Resources:

- A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies (+)
- The dedicated “Lp(a) clinic”: A concept whose time has arrived? (+)
- Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4 (+)
- Statin therapy increases lipoprotein(a) levels (+)
- The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment (+)
- Triglycerides and Cardiovascular Disease (+)
- Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction (+)